Trials / Completed
CompletedNCT01128842
A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor
A Phase 1, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Japanese Subject With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Puma Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, phase 1 study of a single cohort of neratinib (HKI-272) in combination with capecitabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neratinib | 240 mg once daily by mouth. |
| DRUG | Capecitabine | 1500 mg/m\^2 twice daily by mouth. |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2010-05-24
- Last updated
- 2018-12-19
- Results posted
- 2018-12-19
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01128842. Inclusion in this directory is not an endorsement.